Scientists refuse to clinical trials of HIV vaccines

Asked U.S. scientists, cut funding for clinical trials of new vaccines against HIV and lead freed funds for basic research of the human immunodeficiency virus. The declaration was made at a one day conference at the National Institutes of Health. The need for new approaches to the development of vaccines against HIV infection was significantly after the failure of clinical trials of the vaccine from Merck & Co at the end of last year. Lengthy and costly research, both showed in South Africa, Peru, Australia and Jamaica this promising drug was not only reduced, but could slightly increase the risk of HIV infection among the study participants. After the failure of clinical trials hired many experts, the mere possibility of an effective vaccine against HIV. Some members of the academic community should give up completely, the development of vaccines and direct all available resources to the treatment of infections and to prevent already infected. But the majority of the participants in this conference is, prophylactic or therapeutic vaccine is the most promising way to combat the HIV pandemic. "We need to move the focus of the trials of new vaccines for the basic research immunodeficiency virus" - said Anthony Fotsi, director of the National Institute of Allergy and Infectious Diseases, who heads the federal program for the development of a vaccine against HIV. After Fotsi who spend currently in clinical trials of vaccine candidates up to 38 percent of the budget. The bulk of these funds are diverted to laboratory studies of the virus, as well as the creation of new, more sophisticated biological models of HIV infection, the scientists believe.